vs
Bankwell Financial Group, Inc.（BWFG）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
REGENXBIO Inc.的季度营收约是Bankwell Financial Group, Inc.的1.0倍（$30.3M vs $30.3M），Bankwell Financial Group, Inc.同比增速更快（43.3% vs 43.0%），Bankwell Financial Group, Inc.自由现金流更多（$27.1M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs 17.2%）
Bankwell金融集团是美国的银行控股企业，提供个人及商业银行全品类产品服务，包含存款账户、住房贷款、商业信贷、财富管理解决方案，主要服务康涅狄格州的本地社区、零售客户及中小微企业。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
BWFG vs RGNX — 直观对比
营收规模更大
RGNX
是对方的1.0倍
$30.3M
营收增速更快
BWFG
高出0.3%
43.0%
自由现金流更多
BWFG
多$79.9M
$-52.8M
两年增速更快
RGNX
近两年复合增速
17.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $30.3M | $30.3M |
| 净利润 | — | $-67.1M |
| 毛利率 | — | — |
| 营业利润率 | 46.9% | -190.0% |
| 净利率 | — | -221.3% |
| 营收同比 | 43.3% | 43.0% |
| 净利润同比 | — | -31.2% |
| 每股收益（稀释后） | $1.16 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BWFGRGNX
| Q4 25 | $30.3M | $30.3M | ||
| Q3 25 | $28.5M | $29.7M | ||
| Q2 25 | $25.9M | $21.4M | ||
| Q1 25 | $23.6M | $89.0M | ||
| Q4 24 | $21.2M | $21.2M | ||
| Q3 24 | $21.9M | $24.2M | ||
| Q2 24 | $21.9M | $22.3M | ||
| Q1 24 | $22.1M | $15.6M |
净利润BWFGRGNX
| Q4 25 | — | $-67.1M | ||
| Q3 25 | $10.1M | $-61.9M | ||
| Q2 25 | $9.1M | $-70.9M | ||
| Q1 25 | $6.9M | $6.1M | ||
| Q4 24 | — | $-51.2M | ||
| Q3 24 | $1.9M | $-59.6M | ||
| Q2 24 | $1.1M | $-53.0M | ||
| Q1 24 | $3.8M | $-63.3M |
毛利率BWFGRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 52.5% | ||
| Q1 24 | — | 72.6% |
营业利润率BWFGRGNX
| Q4 25 | 46.9% | -190.0% | ||
| Q3 25 | 47.3% | -176.3% | ||
| Q2 25 | 45.5% | -296.3% | ||
| Q1 25 | 38.0% | 13.6% | ||
| Q4 24 | 19.2% | -242.1% | ||
| Q3 24 | 12.4% | -256.6% | ||
| Q2 24 | 6.7% | -251.3% | ||
| Q1 24 | 23.0% | -408.8% |
净利率BWFGRGNX
| Q4 25 | — | -221.3% | ||
| Q3 25 | 35.4% | -208.3% | ||
| Q2 25 | 35.0% | -331.8% | ||
| Q1 25 | 29.2% | 6.8% | ||
| Q4 24 | — | -241.3% | ||
| Q3 24 | 8.8% | -246.3% | ||
| Q2 24 | 5.1% | -237.7% | ||
| Q1 24 | 17.1% | -405.4% |
每股收益（稀释后）BWFGRGNX
| Q4 25 | $1.16 | $-1.30 | ||
| Q3 25 | $1.27 | $-1.20 | ||
| Q2 25 | $1.15 | $-1.38 | ||
| Q1 25 | $0.87 | $0.12 | ||
| Q4 24 | $0.37 | $-0.99 | ||
| Q3 24 | $0.24 | $-1.17 | ||
| Q2 24 | $0.14 | $-1.05 | ||
| Q1 24 | $0.48 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $192.1M | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $301.5M | $102.7M |
| 总资产 | $3.4B | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BWFGRGNX
| Q4 25 | $192.1M | $230.1M | ||
| Q3 25 | $128.2M | $274.2M | ||
| Q2 25 | $142.6M | $323.3M | ||
| Q1 25 | $136.0M | $267.9M | ||
| Q4 24 | $146.1M | $234.7M | ||
| Q3 24 | $145.9M | $255.5M | ||
| Q2 24 | $138.0M | $290.4M | ||
| Q1 24 | $126.2M | $338.7M |
股东权益BWFGRGNX
| Q4 25 | $301.5M | $102.7M | ||
| Q3 25 | $292.8M | $161.5M | ||
| Q2 25 | $283.3M | $213.7M | ||
| Q1 25 | $275.2M | $274.2M | ||
| Q4 24 | $270.5M | $259.7M | ||
| Q3 24 | $267.9M | $301.4M | ||
| Q2 24 | $267.0M | $348.3M | ||
| Q1 24 | $268.0M | $390.7M |
总资产BWFGRGNX
| Q4 25 | $3.4B | $453.0M | ||
| Q3 25 | $3.2B | $525.2M | ||
| Q2 25 | $3.2B | $581.0M | ||
| Q1 25 | $3.2B | $490.9M | ||
| Q4 24 | $3.3B | $466.0M | ||
| Q3 24 | $3.2B | $519.1M | ||
| Q2 24 | $3.1B | $569.4M | ||
| Q1 24 | $3.2B | $629.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $28.3M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $27.1M | $-52.8M |
| 自由现金流率自由现金流/营收 | 89.5% | -174.0% |
| 资本支出强度资本支出/营收 | 3.8% | 1.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $47.0M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流BWFGRGNX
| Q4 25 | $28.3M | $-52.3M | ||
| Q3 25 | $10.3M | $-56.0M | ||
| Q2 25 | $6.5M | $-49.3M | ||
| Q1 25 | $3.9M | $33.6M | ||
| Q4 24 | $29.9M | $-31.6M | ||
| Q3 24 | $-557.0K | $-40.5M | ||
| Q2 24 | $7.1M | $-45.5M | ||
| Q1 24 | $9.0M | $-55.5M |
自由现金流BWFGRGNX
| Q4 25 | $27.1M | $-52.8M | ||
| Q3 25 | $9.9M | $-56.5M | ||
| Q2 25 | $6.1M | $-49.7M | ||
| Q1 25 | $3.8M | $32.6M | ||
| Q4 24 | $29.3M | $-32.7M | ||
| Q3 24 | $-672.0K | $-40.9M | ||
| Q2 24 | $6.8M | $-46.0M | ||
| Q1 24 | $8.9M | $-56.0M |
自由现金流率BWFGRGNX
| Q4 25 | 89.5% | -174.0% | ||
| Q3 25 | 34.9% | -189.9% | ||
| Q2 25 | 23.5% | -232.8% | ||
| Q1 25 | 16.2% | 36.6% | ||
| Q4 24 | 138.6% | -154.2% | ||
| Q3 24 | -3.1% | -168.9% | ||
| Q2 24 | 31.0% | -206.2% | ||
| Q1 24 | 40.5% | -358.5% |
资本支出强度BWFGRGNX
| Q4 25 | 3.8% | 1.7% | ||
| Q3 25 | 1.4% | 1.7% | ||
| Q2 25 | 1.5% | 1.8% | ||
| Q1 25 | 0.4% | 1.2% | ||
| Q4 24 | 2.9% | 5.1% | ||
| Q3 24 | 0.5% | 1.3% | ||
| Q2 24 | 1.7% | 2.1% | ||
| Q1 24 | 0.4% | 3.6% |
现金转化率BWFGRGNX
| Q4 25 | — | — | ||
| Q3 25 | 1.03× | — | ||
| Q2 25 | 0.71× | — | ||
| Q1 25 | 0.57× | 5.53× | ||
| Q4 24 | — | — | ||
| Q3 24 | -0.29× | — | ||
| Q2 24 | 6.39× | — | ||
| Q1 24 | 2.40× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BWFG
暂无分部数据
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
